Exploiting the PI3K/AKT pathway for cancer drug discovery

被引：1818

作者：

Hennessy, BT ^{[1
]}

Smith, DL ^{[1
]}

Ram, PT ^{[1
]}

Lu, YL ^{[1
]}

Mills, GB ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2005年 / 4卷 / 12期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1038/nrd1902

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy. Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway. This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.

引用

页码：988 / 1004

页数：17

共 182 条

[1] Mechanism of activation of protein kinase B by insulin and IGF-1 [J].

Alessi, DR ;

Andjelkovic, M ;

Caudwell, B ;

Cron, P ;

Morrice, N ;

Cohen, P ;

Hemmings, BA .

EMBO JOURNAL, 1996, 15 (23) :6541-6551

[2] MOST HUMAN CARCINOMAS OF THE EXOCRINE PANCREAS CONTAIN MUTANT C-K-RAS GENES [J].

ALMOGUERA, C ;

SHIBATA, D ;

FORRESTER, K ;

MARTIN, J ;

ARNHEIM, N ;

PERUCHO, M .

CELL, 1988, 53 (04) :549-554

[3]

Arboleda MJ, 2003, CANCER RES, V63, P196

[4] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[5] The PIK3CA gene is mutated with high frequency in human breast cancers [J].

Bachman, KE ;

Argani, P ;

Samuels, Y ;

Silliman, N ;

Ptak, J ;

Szabo, S ;

Konishi, H ;

Karakas, B ;

Blair, BG ;

Lin, C ;

Peters, BA ;

Velculescu, VE ;

Park, BH .

CANCER BIOLOGY & THERAPY, 2004, 3 (08) :772-775

[6] Somatic mutations of EGFR in colorectal cancers and glioblastomas [J].

Barber, TD ;

Vogelstein, B ;

Kinzler, KW ;

Velculescu, VE .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) :2883-2883

[7] Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors [J].

Barnett, SF ;

Defeo-Jones, D ;

Fu, S ;

Hancock, PJ ;

Haskell, KM ;

Jones, RE ;

Kahana, JA ;

Kral, AM ;

Leander, K ;

Lee, LL ;

Malinowski, J ;

McAvoy, EM ;

Nahas, DD ;

Robinson, RG ;

Huber, HE .

BIOCHEMICAL JOURNAL, 2005, 385 :399-408

[8] MOLECULAR ALTERATIONS OF THE AKT2 ONCOGENE IN OVARIAN AND BREAST CARCINOMAS [J].

BELLACOSA, A ;

DEFEO, D ;

GODWIN, AK ;

BELL, DW ;

CHENG, JQ ;

ALTOMARE, DA ;

WAN, MH ;

DUBEAU, L ;

SCAMBIA, G ;

MASCIULLO, V ;

FERRANDINA, G ;

PANICI, PB ;

MANCUSO, S ;

NERI, G ;

TESTA, JR .

INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (04) :280-285

[9] A RETROVIRAL ONCOGENE, AKT, ENCODING A SERINE-THREONINE KINASE CONTAINING AN SH2-LIKE REGION [J].

BELLACOSA, A ;

TESTA, JR ;

STAAL, SP ;

TSICHLIS, PN .

SCIENCE, 1991, 254 (5029) :274-277

[10] MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network [J].

Bhalla, US ;

Ram, PT ;

Iyengar, R .

SCIENCE, 2002, 297 (5583) :1018-1023

← 1 2 3 4 5 6 7 8 9 10 →